Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.96 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | GID4 | Q8IVV7 | 3/20 | 0.68 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478499 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL30721685 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL325083 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL12046710 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1668148 | 1.00 | PRCP (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1694774 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A | |
| Hydrochloric Acid SCHEMBL1735508 | 0.98 | GAA (1.00) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1694744 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL1694844 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL19610875 | 0.98 | PRCP (0.96) | PRCPGAARECQLGID4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-117263929-A | Preparation method of circularly polarized light-emitting heat-activating delayed fluorescent material | 宁波工程学院 | 2023-12-22 | — | — | CN | claimed |
| CN-111574448-B | Preparation method of phenyl tetrahydroisoquinoline | 广东东阳光药业股份有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-111621805-B | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2022-02-18 | — | — | CN | claimed |
| CN-111943134-A | Room-temperature dehydrogenation reaction system of photocatalytic organic liquid hydrogen storage material and preparation method and application thereof | 中国科学院理化技术研究所 | 2020-11-17 | — | — | CN | claimed |
| CN-111925266-A | Preparation method of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline | 西华大学 | 2020-11-13 | — | — | CN | claimed |
| CN-111621805-A | Method for preparing 3, 4-dihydroisoquinoline by electrocatalytic selective dehydrogenation | 天津大学 | 2020-09-04 | — | — | CN | claimed |
| CN-111574448-A | Preparation method of phenyltetrahydroisoquinoline | 广东东阳光药业有限公司 | 2020-08-25 | — | — | CN | claimed |
| EP-2406257-B1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | MEGAFINE PHARMA P LTD (IN) | 2019-08-07 | — | — | EP | claimed |
| CN-109438348-A | The preparation method and preparation method thereof of one kind (S) -1- phenyl -1,2,3,4- tetrahydroisoquinoline | 凯瑞斯德生化(苏州)有限公司 | 2019-03-08 | — | — | CN | claimed |
| EP-1879867-A2 | INTERMEDIATES FOR PREPARING SOLIFENACIN | Teva Pharmaceutical Industries Ltd (IL) | 2008-01-23 | — | — | EP | claimed |
| CN-101094672-A | 4-phenyl substituted tetrahydroisoquinolines and their use to block reuptake of norepinephrine, dopamine, and 5-hydroxytryptamine | AMR TECHNOLOGY INC (US) | 2007-12-26 | — | — | CN | claimed |
| WO-2007076116-A2 | INTERMEDIATES FOR PREPARING SOLIFENACIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| US-6967199-B2 | Substituted diamine derivatives useful as motilin antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-11-22 | — | — | US | claimed |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | JOHNSON SIGMONG G (US) | 2003-10-30 | — | — | US | claimed |
| CN-1440390-A | Substituted diamine derivatives as motilin antagonists | ORTHO MCNEIL PHARM INC (US) | 2003-09-03 | — | — | CN | claimed |
| CN-1413197-A | 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | ALBANY MOLECULAR RES CO (US) | 2003-04-23 | — | — | CN | claimed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | claimed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | PRCP 1396/4885GAA 447/4885RECQL 376/4885 |
| US-20030203906-A1 | A phenylamide derivatives for treating gastrointestinal reflux disorders, eating disorder obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | PRCP 1213/4885GAA 477/4885RECQL 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.